CN117642401A - 作为atr抑制剂的萘啶衍生物及其制备方法 - Google Patents

作为atr抑制剂的萘啶衍生物及其制备方法 Download PDF

Info

Publication number
CN117642401A
CN117642401A CN202280050285.2A CN202280050285A CN117642401A CN 117642401 A CN117642401 A CN 117642401A CN 202280050285 A CN202280050285 A CN 202280050285A CN 117642401 A CN117642401 A CN 117642401A
Authority
CN
China
Prior art keywords
membered
group
heterocycloalkyl
compound
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280050285.2A
Other languages
English (en)
Chinese (zh)
Inventor
谢雨礼
刘文中
钱立晖
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wigen Biomedicine Technology Shanghai Co Ltd
Original Assignee
Wigen Biomedicine Technology Shanghai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wigen Biomedicine Technology Shanghai Co Ltd filed Critical Wigen Biomedicine Technology Shanghai Co Ltd
Publication of CN117642401A publication Critical patent/CN117642401A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN202280050285.2A 2021-08-11 2022-08-11 作为atr抑制剂的萘啶衍生物及其制备方法 Pending CN117642401A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN2021109198126 2021-08-11
CN202110919812 2021-08-11
CN202111188963 2021-10-12
CN2021111889635 2021-10-12
CN2022109184433 2022-08-01
CN202210918443 2022-08-01
PCT/CN2022/111893 WO2023016529A1 (zh) 2021-08-11 2022-08-11 作为atr抑制剂的萘啶衍生物及其制备方法

Publications (1)

Publication Number Publication Date
CN117642401A true CN117642401A (zh) 2024-03-01

Family

ID=85199870

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280050285.2A Pending CN117642401A (zh) 2021-08-11 2022-08-11 作为atr抑制剂的萘啶衍生物及其制备方法

Country Status (8)

Country Link
US (1) US20240317741A1 (enExample)
EP (1) EP4385992A4 (enExample)
JP (1) JP2024529070A (enExample)
CN (1) CN117642401A (enExample)
AU (1) AU2022325376A1 (enExample)
CA (1) CA3227336A1 (enExample)
TW (1) TWI831325B (enExample)
WO (1) WO2023016529A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20260019479A (ko) 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Ras 관련 질환 또는 장애를 위한 병용 요법
CN121889155A (zh) 2023-08-07 2026-04-17 锐新医药公司 用于治疗ras蛋白相关疾病或病症的rmc-6291
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025217307A1 (en) 2024-04-09 2025-10-16 Revolution Medicines, Inc. Methods for predicting response to a ras(on) inhibitor and combination therapies
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026112260A1 (en) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106795156A (zh) * 2014-08-04 2017-05-31 拜耳制药股份公司 2‑(吗啉‑4‑基)‑1，7‑萘啶
WO2018153970A1 (en) * 2017-02-24 2018-08-30 Bayer Pharma Aktiengesellschaft Solid forms of 2-[(3r)-3-methylmorpholin-4-yl]-4-(1-methyl-1h-pyrazol-5-yl)-8-(1h-pyrazol-5-yl)-1,7-naphthyridine
CN108699057A (zh) * 2016-01-14 2018-10-23 拜耳医药股份公司 5-取代的2-(吗啉-4-基)-1,7-萘啶
WO2022063308A1 (zh) * 2020-09-27 2022-03-31 南京明德新药研发有限公司 一类1,7-萘啶类化合物及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210097124A (ko) * 2018-10-30 2021-08-06 리페어 세라퓨틱스 인크. 화합물, 약제 조성물, 및 화합물 제조 방법 및 atr 키나제 억제제로서의 이것들의 사용 방법

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106795156A (zh) * 2014-08-04 2017-05-31 拜耳制药股份公司 2‑(吗啉‑4‑基)‑1，7‑萘啶
CN108699057A (zh) * 2016-01-14 2018-10-23 拜耳医药股份公司 5-取代的2-(吗啉-4-基)-1,7-萘啶
WO2018153970A1 (en) * 2017-02-24 2018-08-30 Bayer Pharma Aktiengesellschaft Solid forms of 2-[(3r)-3-methylmorpholin-4-yl]-4-(1-methyl-1h-pyrazol-5-yl)-8-(1h-pyrazol-5-yl)-1,7-naphthyridine
WO2022063308A1 (zh) * 2020-09-27 2022-03-31 南京明德新药研发有限公司 一类1,7-萘啶类化合物及其应用

Also Published As

Publication number Publication date
CA3227336A1 (en) 2023-02-16
EP4385992A1 (en) 2024-06-19
EP4385992A4 (en) 2025-12-03
AU2022325376A1 (en) 2024-02-22
TWI831325B (zh) 2024-02-01
WO2023016529A1 (zh) 2023-02-16
JP2024529070A (ja) 2024-08-01
US20240317741A1 (en) 2024-09-26
TW202306955A (zh) 2023-02-16

Similar Documents

Publication Publication Date Title
TWI831325B (zh) 作為atr抑制劑的萘啶衍生物及其製備方法
CN115335379B (zh) 含螺环的喹唑啉化合物
CN117751116A (zh) 作为KRas G12D抑制剂的稠环化合物
CN118613478A (zh) Kif18a抑制剂
CN116390728B (zh) 喹唑啉衍生物及其制备方法和用途
CN113105448A (zh) 芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用
CN116323617B (zh) 5,6-二氢吡嗪并[2,3-c]异喹啉化合物
CN115867542B (zh) 新型苯并咪唑化合物
CN116253747A (zh) 新型高喜树碱衍生物、含其的组合物和其用途
CN118119622A (zh) 作为shp2抑制剂的稠环化合物
WO2025092773A1 (zh) 作为myt1抑制剂的化合物
CN120826398A (zh) 作为DGKζ抑制剂的化合物
CN118574825A (zh) 作为fak抑制剂的化合物及其用途
KR20260054707A (ko) Cdk4 키나아제 억제제로 사용되는 화합물 및 이의 응용
CN119998274A (zh) Ulk抑制剂
CN115698000B (zh) 新型吡嗪化合物
CN118525015A (zh) 作为fak抑制剂的化合物及其用途
CN117295743A (zh) 作为Wee-1抑制剂的吡咯并嘧啶衍生物
CN116867787A (zh) 吡唑并[3,4-d]嘧啶-3-酮衍生物
CN118434729A (zh) 作为hpk1抑制剂的稠环化合物
CN116848117A (zh) 作为Wee-1抑制剂的稠环化合物
CN117222648B (zh) 作为Wee-1抑制剂的稠环化合物及其制备方法和用途
CN117222649B (zh) 吡咯并嘧啶衍生物及其制备方法和用途
CN116783194B (zh) 含螺环的喹唑啉衍生物
CN117412971B (zh) 含吡嗪结构的吡咯并嘧啶衍生物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination